Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain

Article Details

Authors
Darío Antolín-Amerigo, Isabel A Tabar, Maria del Mar Fernández-Nieto, Anna M Callejo-Melgosa, Francisco J Muñoz-Bellido, José C Martínez-Alonso, Jorge D Méndez-Alcalde, Marta Reche, Ana Rodríguez-Trabado, Ana Rosado-Ingelmo, Alicia Alonso-Gómez, Rosa Blanco-González, José A Alvarez-Fernandez, Isabel Botella, Ana Valls, Mercedes Cimarra, Carlos Blanco

Article Type
Original Research

DOI
10.7573/dic.212309

Related Articles

Article Page

Abstract

Background: Five-grass pollen tablet is an effective and well-tolerated therapy for patients with allergic rhinoconjunctivitis (ARC). This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing this treatment.

Methods: This was a cross-sectional, multicentre, observational, naturalistic study, following a discontinuous pre- and coseasonal five-grass pollen regimen over two seasons in Spain (2012, 2013). The HRQoL of the patients was measured with the specific Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for adults, adolescent (AdolRQLQ), or paediatric (PRQLQ) patients. Treatment satisfaction was assessed by the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire. Patients/investigators were surveyed on beliefs and attitudes towards the five-grass pollen tablet. ARC evolution according to allergic rhinitis and its impact on asthma (ARIA) criteria and treatment adherence were evaluated.

Results: Among the 591 ARC patients included, the mean (SD) HRQoL scores were 1.40 (1.1) in adults, 1.33 (1.1) in adolescents, and 1.15 (1.1) in children, indicating low levels of impairment (scale 0–6). ESPIA answers showed high levels of satisfaction, with an average score of 69.2 (scale 0–100). According to ARIA criteria, 88.2% of patients reported improvement of ARC. Moreover, this was accompanied by a reduced use of symptomatic medication. Adherence to treatment was estimated at 96.8%. In general, both patients and specialists exhibited a positive attitude towards five-grass pollen tablet treatment.

Conclusion: ARC patients treated with five-grass pollen tablet showed favourable levels of HRQoL and treatment satisfaction, with concomitant improvements in ARC and symptomatic medication use, which translated into high levels of treatment adherence and a positive attitude towards five-grass pollen tablet.

Keywords: sublingual immunotherapy, pollen, rhinitis allergic seasonal, conjunctivitis allergic, health-related quality of life, patient satisfaction, symptom improvement, cross-sectional study.

Citation: Antolín-Amerigo D, Tabar IA, Fernández-Nieto M, Callejo-Melgosa AM, Muñoz-Bellido FJ, Martínez-Alonso JC, Méndez-Alcalde JD, Reche M, Rodríguez-Trabado A, Rosado-Ingelmo A, Alonso-Gómez A, Blanco-González R, Alvarez-Fernandez JA, Botella I, Valls A, Cimarra M, Blanco C. Satisfaction and quality of life of allergic patients following sublingual fivegrass pollen tablet immunotherapy in Spain. Drugs in Context 2017; 6: 212309. DOI: 10.7573/dic.212309

Contributions: Stallergenes was responsible for the study design, collection, analysis and interpretation of data, and writing the manuscript. All authors contributed by data acquisition, critical appraisal of the manuscript, and approval of the final version of the manuscript. All authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure and potential conflict of interest: All authors with the exception of Isabel Botella received personal fees from Stallergenes for conducting the study. Isabel Botella is a full-time employee of Stallergenes Iberica SA. The international Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interest form for the authors is available for download at: http://www.drugsincontext.com/wp-content/uploads/2017/10/dic.212309-COI.pdf

Acknowledgements: The authors thank the scientific and editorial assistance provided by IMS Health and NewMed Publishing funded by Stallergenes Iberica SA. The authors also thank all participating patients and investigators.

Funding declaration: This study was funded by Stallergenes Iberica SA.

Copyright: Copyright © 2017 Antolín-Amerigo D, Tabar IA, Fernández-Nieto M, Callejo-Melgosa AM, Muñoz-Bellido FJ, Martínez-Alonso JC, Méndez-Alcalde JD, Reche M, Rodríguez-Trabado A, Rosado-Ingelmo A, Alonso-Gómez A, Blanco-González R, Alvarez-Fernandez JA, Botella I, Valls A, Cimarra M, Blanco C. Distributed under the terms of the Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2017 Antolín-Amerigo D, Tabar IA, Fernández-Nieto M, Callejo-Melgosa AM, Muñoz-Bellido FJ, Martínez-Alonso JC, Méndez-Alcalde JD, Reche M, Rodríguez-Trabado A, Rosado-Ingelmo A, Alonso-Gómez A, Blanco-González R, Alvarez-Fernandez JA, Botella I, Valls A, Cimarra M, Blanco C. https://doi.org/10.7573/dic.212309. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: http://www.drugsincontext.com/satisfaction-and-quality-of-life-of-allergic-patients-following-sublingual-five-grass-pollen-tablet-immunotherapy-in-spain

Correspondence: Carlos Blanco, Allergy Department, Hospital Universitario de La Princesa, 28006, Madrid, Spain. cblague@gmail.com

Provenance: submitted; externally peer reviewed.

Submitted: 15 May 2017; Peer review comments to author: 30 June 2017; Revised manuscript received: 20 September 2017; Accepted: 20 September 2017; Published: 29 November 2017

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office: dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes: david.hughes@bioexcelpublishing.com

Download free full text PDF